Letter to the Editors-in-ChiefAssociation of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: An updated meta-analysis
Section snippets
Conflict of interest statement
No conflicts of interest.
Acknowledgements
This work was supported by National 973 Basic Research Program of China Grants (2010CB732605 and 2011CB503906), State Program of National Natural Science Foundation of China for Innovative Research Group (81021001), National Natural Science Foundation of China Grants (30900607 and 81000126), Shandong Provincial Natural Science Foundation of China Grants (ZR2009CM021-2009ZRB01192), and Graduate Independent Innovation Foundation of Shandong University (yzc11073).
References (22)
- et al.
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lancet
(2010) - et al.
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
Am Heart J
(2010) - et al.
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
J Am Coll Cardiol
(2008) - et al.
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Lancet
(2009) - et al.
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis
Am J Cardiol
(2009) - et al.
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy
J Cardiol
(2011) - et al.
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
J Am Coll Cardiol
(2010) - et al.
Cytochrome p-450 polymorphisms and response to clopidogrel
N Engl J Med
(2009) - et al.
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
N Engl J Med
(2010) - et al.
Genetic determinants of response to clopidogrel and cardiovascular events
N Engl J Med
(2009)
Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel
Circ J
Cited by (21)
Role of phenotypic and genetic testing in managing clopidogrel therapy
2014, BloodCitation Excerpt :The association between carriers of CYP2C19 LOF alleles and an increased risk of cardiovascular events in clopidogrel-treated patients has been investigated in patients with ACS, PCI, stable ischemic heart disease, and atrial fibrillation. MACE and stent thrombosis have been used as clinical outcomes in >30 observational studies and 6 genetic substudies nested in RCTs, which included >42 000 patients (Table 6).29,53,82-90 There was also an association between LOF alleles and MACE, which on indirect comparison of 2 separate meta-analyses suggests a greater risk in patients undergoing PCI.
The gain-of-function variant allele CYP2C19*17: A double-edged sword between thrombosis and bleeding in clopidogrel-treated patients
2012, Journal of Thrombosis and HaemostasisPharmacogenomics in Asians: Differences and similarities with other human populations
2023, Expert Opinion on Drug Metabolism and ToxicologyAcute Respiratory Distress Syndrome Associated With Clopidogrel in a Young Male Patient
2019, Frontiers in Medicine
- 1
The first three authors contributed equally to this work.